Akcea Therapeutics (AKCA) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Akcea Reports Financial Results and Highlights for Third Quarter 2017
November 6, 2017 4:05 PM ESTSubmitted marketing authorization applications in the US, EU and Canada for volanesorsen in FCS
 Expanded leadership team to support global commercial launch of volanesorsen
      Conference Call Webcast Monday, November 6, 4:30 p.m. ET at www.akceatx.com
CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:... More
